GAMMA Investing’s Inovio Pharmaceuticals INO Stock Holding History

GAMMA Investing’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-24	Closed	-$139	–	3802
2024 Q3	$139	Buy	+24	New	+$198	﹤0.01%	3544

Other funds holding INO

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

GAMMA Investing's INO Position: Q4 2024 in Review

GAMMA Investing sold out of Inovio Pharmaceuticals (INO) in Q4 2024, closing a stake of 24 shares — an estimated $139 sold.

GAMMA Investing first reported a position in INO in Q3 2024 and held it in 1 quarter. The position peaked at $139 in Q3 2024. 104 funds tracked by Wall St. Rank hold INO as of Q4 2024.

GAMMA Investing reported no remaining Inovio Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
GAMMA Investing sold 24 Inovio Pharmaceuticals shares in Q4 2024, an estimated $139.
GAMMA Investing first reported a position in Inovio Pharmaceuticals in Q3 2024 and held it in 1 quarter.
GAMMA Investing's Inovio Pharmaceuticals position peaked at $139 in Q3 2024.
104 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2024.

Based on GAMMA Investing's 13F filing for Q4 2024, filed 3 Jan 2025.